Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …

ABSTRACT RNA therapeutics comprise a diverse group of oligonucleotide-based drugs
such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short …

The blood–brain barrier (BBB) limits the delivery of therapeutics to the brain but also
represents the main gate for nutrient entrance. Targeting the natural transport mechanisms …

Peptides comprise a versatile class of biomolecules that present a unique chemical space
with diverse physicochemical and structural properties. Some classes of peptides are able to …

The blood–brain barrier is a major obstacle in treating brain-related disorders, as it does not
allow the delivery of drugs into the brain. We developed a method for predicting blood–brain …

Liposomes are versatile carriers that can encapsulate various drugs; however, for delivery to
the brain, they must be modified with a targeting ligand or other modifications to provide …

Blood-brain barrier (BBB) is a major barrier to drug delivery into the brain in the treatment of
central nervous system (CNS) diseases. Blood-brain barrier penetrating peptides (BBPs), a …

In the last few decades, adverse reactions to pharmaceuticals have been evaluated using
2D in vitro models and animal models. However, with increasing computational power, and …

Cell penetrating peptides (CPPs) can be broadly defined as relatively short synthetic, protein
derived or chimeric peptides. Their most remarkable property is their ability to cross cell …

The blood-brain barrier (BBB) is the primary barrier with a highly selective semipermeable
border between blood vascular endothelial cells and the central nervous system. Since BBB …